CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03635892
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:17.369015+00:00
Published At: 2025-09-22T00:00:00+00:00
Record Updated At: 2025-09-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma", "Unclassified Renal Cell Carcinoma", "Papillary Renal Cell Carcinoma", "Fumarate Hydratase Deficient Renal Cell Carcinoma", "Succinate Dehydrogenase Deficient Renal Cell Carcinoma", "Collecting Duct Renal Cell Carcinoma", "Chromophobe Renal Cell Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-09-22"
protocolSection.identificationModule.nctId: "NCT03635892"
protocolSection.identificationModule.officialTitle: "A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.